Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Arpan A. Patel
Observed name:
Arpan Patel
Institution:
University of Rochester Medicine
Observed institutions:
Cleveland Clinic,
University of Rochester Medicine,
Cleveland Clinic Lerner College of Medicine,
University of Rochester
ORCID:
0009-0006-7592-0890
Observed ORCID:
0009-0006-7592-0890
OpenAlex ID:
A5078428014
Deep-Learning Serial CT Prediction of Survival in Immunotherapy-Treated Non–Small Cell Lung Cancer
2026
·
Chiharu Sako
, Brenda F. Kurland
, et al.
·
JAMA Network Open
·
15
C1–2 hypermobility and its impact on the spinal cord: a finite element analysis
2024
·
Arpan A. Patel
, Jacob K. Greenberg
, et al.
·
Journal of Neurosurgery Spine
·
8
Review of mechanisms of expandable spine surgery devices
2024
·
Yuncong Mao
, Arpan A. Patel
, et al.
·
Expert Review of Medical Devices
·
5
Radiographic Indicators of Craniocervical Instability: Analyzing Variance of Normative Supine and Upright Imaging in a Healthy Population
2024
·
Alan J. Gordillo
, Matt Magro
, et al.
·
Clinical Spine Surgery A Spine Publication
·
2
AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC.
2023
·
George R. Simon
, Petr Jordan
, et al.
·
Journal of Clinical Oncology
·
2
Radiographic Alignment Parameters for Lumbosacral Reconstruction in Patients With Altered S1 Morphology
2024
·
Arpan A. Patel
, Shaarada Srivatsa
, et al.
·
Global Spine Journal
·
1
Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy.
2023
·
Chiharu Sako
, Petr Jordan
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Abstract 5618: Multi-institutional validation of a radiomics-based artificial intelligence method for predicting response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV NSCLC
2023
·
Ravi B. Parikh
, Petr Jordan
, et al.
·
Cancer Research
·
1
Real-world evaluation of a deep learning–based serial CT imaging biomarker with variable thoracic and abdominopelvic coverage in metastatic colorectal and kidney cancers.
2026
·
Taly Schmidt
, Chiharu Sako
, et al.
·
Journal of Clinical Oncology
Artificial intelligence–enabled analysis of unstructured EHR data for identification of actionable HER2-low breast cancer phenotypes.
2026
·
Arpan Patel
, Anna Williford
, et al.
·
Journal of Clinical Oncology
PDF
Abstract 2775: Deep-learning CT biomarker improves early efficacy detection in simulated randomized phase II NSCLC trials.
2026
·
Chiharu Sako
, Brenda F. Kurland
, et al.
·
Cancer Research
Abstract A029: Validation of a Deep Learning Serial Computed Tomography Response Biomarker for Predicting Overall Survival in Metastatic Kidney Cancer Treated with Immune Checkpoint Inhibitors
2025
·
Chiharu Sako
, Taly G. Schmidt
, et al.
·
Clinical Cancer Research
Retrospective single-institution application of a deep learning–based radiomic score in metastatic NSCLC: Potential impact on first-line treatment decisions and outcomes.
2025
·
Nicholas Campbell Love
, Karishma Sewaramani
, et al.
·
Journal of Clinical Oncology
Abstract 736: Deep learning response score using baseline and 12-week RECIST chest CTs enhances overall survival (OS) prediction in advanced NSCLC: external validation in a trial with dostarlimab
2025
·
Brenda F. Kurland
, Chiharu Sako
, et al.
·
Cancer Research
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
2023
·
Dali Edwards
, Gahyun Gim
, et al.
·
JCO Oncology Practice
PDF
1296 Radiomics-based multi-modal prediction of treatment response to PD-1/PD-L1 immune checkpoint inhibitor (ICI) therapy in stage IV non-small cell lung carcinoma (mNSCLC)
2022
·
Ravi Parikh
, Petr Jordan
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
16
Citation count:
35
H-index:
3
I10-index:
1
Year
Topic
Type